This recombinant monoclonal antibody is designed as a research-grade biosimilar to IPH5301, targeting NT5E (ecto-5'-nucleotidase), also known as CD73. NT5E is a cell surface enzyme that catalyzes the conversion of extracellular adenosine monophosphate to adenosine, playing a critical role in purinergic signaling and immune regulation. By generating adenosine in the tumor microenvironment, NT5E contributes to immunosuppression by inhibiting T cell and NK cell activity while promoting regulatory T cell function. Elevated NT5E expression has been associated with multiple cancers, including triple-negative breast cancer, ovarian cancer, melanoma, and colorectal cancer, where it correlates with poor prognosis and immune evasion.
IPH5301 is a therapeutic antibody developed to block NT5E enzymatic activity, thereby reducing adenosine-mediated immunosuppression and enhancing anti-tumor immune responses. This biosimilar provides researchers with a valuable tool for investigating NT5E-dependent mechanisms in cancer immunity, adenosine signaling pathways, and immune checkpoint regulation. It supports studies exploring combination immunotherapy strategies and tumor microenvironment modulation.
Email: support@cusabio.com
Distributors Worldwide